ANTERIS TECHNOLOGIES GLOBAL CORP. - Announcements

6.26%

$5.60

Market Cap $86.68M

Healthcare Medical Devices

Anteris Technologies Global Corp. is a structural heart company, which is engaged in... Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

AVR	Capital Raise	PRICE SENSITIVE	27/10/21	173.09KB	Share
AVR	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	26/08/21	956.51KB	Share
AVR	Capital Raise	PRICE SENSITIVE	02/08/21	189.44KB	Share
AVR	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/21	322.86KB	Share
AVR	Trading Halt	PRICE SENSITIVE	29/07/21	631.2KB	Share
AVR	AGM Chairman's address and CEO Presentation	PRICE SENSITIVE	15/07/21	7.08MB	Share
AVR	ADAPT Conduit Proof of Concept Study finds no Calcification	PRICE SENSITIVE	15/06/21	105.26KB	Share
AVR	Capital Raise	PRICE SENSITIVE	24/05/21	164.94KB	Share
AVR	Trading Halt	PRICE SENSITIVE	21/05/21	287.87KB	Share
AVR	Pause in Trading	PRICE SENSITIVE	21/05/21	116.45KB	Share
AVR	ComASUR Key Milestone	PRICE SENSITIVE	27/04/21	191.15KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	22/04/21	319.41KB	Share
AVR	Expanded Funding Package	PRICE SENSITIVE	12/04/21	225.58KB	Share
AVR	Anti-Calcification Study	PRICE SENSITIVE	29/03/21	204.67KB	Share
AVR	Response to ASX Price and Volume Query	PRICE SENSITIVE	09/03/21	306.69KB	Share
AVR	Preliminary Financial Report	PRICE SENSITIVE	18/02/21	228.83KB	Share
AVR	Full Year Statutory Accounts	PRICE SENSITIVE	18/02/21	1.73MB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	22/01/21	295.12KB	Share
AVR	First Tranche Closing - Mercer	PRICE SENSITIVE	20/01/21	179.92KB	Share
AVR	Reinstatement to Official Quotation	PRICE SENSITIVE	06/01/21	86.22KB	Share
AVR	Funding Package	PRICE SENSITIVE	06/01/21	294.48KB	Share
AVR	Research and Development Advance	PRICE SENSITIVE	04/01/21	158.9KB	Share
AVR	Placement	PRICE SENSITIVE	30/12/20	215.3KB	Share
AVR	Suspension from Official Quotation	PRICE SENSITIVE	29/12/20	240.75KB	Share
AVR	Trading Halt	PRICE SENSITIVE	23/12/20	587.85KB	Share
AVR	DurAVR SELECTED AS A BEST INNOVATION - PCR LONDON VALVES	PRICE SENSITIVE	23/11/20	153.04KB	Share
AVR	Anti-calcification Comparison Study Interim Results	PRICE SENSITIVE	10/11/20	160.09KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	16/10/20	272.3KB	Share
AVR	Anteris Granted US Patent	PRICE SENSITIVE	08/09/20	177.64KB	Share
AVR	Appendix 4D and Half Yearly Financial Report	PRICE SENSITIVE	20/08/20	1.39MB	Share
AVR	Unusual Trading Patterns	PRICE SENSITIVE	30/07/20	114.22KB	Share
AVR	Response to Market Speculation	PRICE SENSITIVE	24/07/20	595.16KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	22/07/20	777.31KB	Share
AVR	Presentation - Symposium on Next Generation Technologies	PRICE SENSITIVE	21/07/20	2.54MB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	22/04/20	271.76KB	Share
AVR	First in human trial commences	PRICE SENSITIVE	27/03/20	100.3KB	Share
AVR	Preliminary Financial Report	PRICE SENSITIVE	28/02/20	237.04KB	Share
AVR	Appendix 4E and Full Year Accounts	PRICE SENSITIVE	28/02/20	1.42MB	Share
AVR	Finalisation of License with 4C Medical	PRICE SENSITIVE	03/02/20	153.58KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	230.25KB	Share
AVR	SAVR Clinical Trial	PRICE SENSITIVE	22/01/20	137.57KB	Share
AVR	Update to LeMaitre Vascular deal	PRICE SENSITIVE	09/12/19	181.07KB	Share
AVR	Response to ASX Price and Volume Query	PRICE SENSITIVE	19/11/19	703.39KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/19	282KB	Share
AVR	Reinstatement to Official Quotation	PRICE SENSITIVE	14/10/19	71.87KB	Share
AVR	CardioCel and VascuCel rights sold to LeMaitre Vascular	PRICE SENSITIVE	14/10/19	111.96KB	Share
AVR	Extension for Voluntary Suspension	PRICE SENSITIVE	02/09/19	78.92KB	Share
AVR	Appendix 4D and Half Yearly Financial Report	PRICE SENSITIVE	23/08/19	1001.93KB	Share
AVR	Suspension from Official Quotation - Annual Listing Fee	PRICE SENSITIVE	22/08/19	440.19KB	Share
AVR	Response to ASX Appendix 4C Query	PRICE SENSITIVE	15/08/19	699.37KB	Share
AVR	Notice to terminate distribution agreement	PRICE SENSITIVE	08/08/19	75.71KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/19	232.24KB	Share
AVR	AHZ completes sale of part of Infusion business	PRICE SENSITIVE	31/05/19	93.28KB	Share
AVR	2019 AGM Presentation	PRICE SENSITIVE	14/05/19	2.59MB	Share
AVR	Admedus to divest part of Infusion business	PRICE SENSITIVE	13/05/19	121.62KB	Share
AVR	Facility Agreement with SIO Partners LP	PRICE SENSITIVE	08/05/19	121.62KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	26/04/19	267.15KB	Share
AVR	Transaction Terminated and Subsidiary Appoints Administrator	PRICE SENSITIVE	23/04/19	94.56KB	Share
AVR	Response to ASX Aware Query	PRICE SENSITIVE	23/04/19	270.52KB	Share
AVR	Suspension from Official Quotation	PRICE SENSITIVE	17/04/19	290.06KB	Share
AVR	Trading Halt	PRICE SENSITIVE	15/04/19	284.95KB	Share
AVR	Response to ASX Price and Volume Query	PRICE SENSITIVE	10/04/19	480.15KB	Share
AVR	Share Sale Agreement to sell Admedus Vaccines	PRICE SENSITIVE	10/04/19	104.82KB	Share
AVR	Trading Halt	PRICE SENSITIVE	10/04/19	150.44KB	Share
AVR	Pause In Trading	PRICE SENSITIVE	10/04/19	115.22KB	Share
AVR	Preliminary Final Report for period to 31 December 2018	PRICE SENSITIVE	01/03/19	157.47KB	Share
AVR	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	01/03/19	1.69MB	Share
AVR	Response to ASX Appendix 4C Query	PRICE SENSITIVE	20/02/19	259.97KB	Share
AVR	Promising Interim Results from TAVR Animal Study	PRICE SENSITIVE	19/02/19	100.82KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	21/01/19	219.42KB	Share
AVR	Reinstatement to Official Quotation	PRICE SENSITIVE	28/11/18	68.65KB	Share
AVR	Admedus Prospectus - rights issue	PRICE SENSITIVE	28/11/18	655.56KB	Share
AVR	Admedus launches rights issue	PRICE SENSITIVE	28/11/18	185.75KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	01/11/18	365.86KB	Share
AVR	Appendix 3B - Star Bright Placement Issue	PRICE SENSITIVE	05/09/18	844.58KB	Share
AVR	Appendix 4D and Half Yearly Financial Report	PRICE SENSITIVE	03/09/18	1.02MB	Share
AVR	Admedus Secures Strategic Investor	PRICE SENSITIVE	03/09/18	242.06KB	Share
AVR	Distribution agreement renewed for infusion supply chain	PRICE SENSITIVE	09/08/18	30.8KB	Share
AVR	Voluntary Suspension	PRICE SENSITIVE	06/08/18	276.07KB	Share
AVR	Trading Halt Announcement - System Upgrade	PRICE SENSITIVE	06/08/18	220.36KB	Share
AVR	Trading Halt	PRICE SENSITIVE	02/08/18	636.94KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/18	269.99KB	Share
AVR	Major Milestone for TAVR As Trials Commence	PRICE SENSITIVE	11/07/18	615.62KB	Share
AVR	New distribution agreement signed for Italy	PRICE SENSITIVE	09/07/18	32.52KB	Share
AVR	MOU signed for Admedus Vaccines	PRICE SENSITIVE	27/06/18	633.37KB	Share
AVR	Conclusion of relationship with Go Medical Industries	PRICE SENSITIVE	07/06/18	83.13KB	Share
AVR	Trading Halt	PRICE SENSITIVE	06/06/18	104.88KB	Share
AVR	Appointment of Director	PRICE SENSITIVE	23/05/18	64.89KB	Share
AVR	Additional patents filed for TAVR device project	PRICE SENSITIVE	23/05/18	83.52KB	Share
AVR	TAVR project progresses to animal trials	PRICE SENSITIVE	22/05/18	100KB	Share
AVR	Admedus enters distribution agreement for Spain	PRICE SENSITIVE	17/05/18	74.78KB	Share
AVR	Share Purchase Plan	PRICE SENSITIVE	10/05/18	902.27KB	Share
AVR	Admedus secures further funding with Placement and SPP	PRICE SENSITIVE	10/05/18	85.36KB	Share
AVR	Trading Halt	PRICE SENSITIVE	08/05/18	509.84KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/18	139.54KB	Share
AVR	Investor signs Letter of Intent to fund Admedus Vaccines	PRICE SENSITIVE	27/04/18	74.84KB	Share
AVR	Admedus TAVR gaining momentum with new patent applications	PRICE SENSITIVE	19/04/18	400.23KB	Share
AVR	Admedus update on TAVR project	PRICE SENSITIVE	12/03/18	404.36KB	Share
AVR	Admedus contracts with US Group Purchasing Organisation	PRICE SENSITIVE	09/03/18	355.81KB	Share
AVR	CANADA REGULATORY APPROVAL GRANTED - CARDIOCEL 3D, VASCUCEL	PRICE SENSITIVE	07/03/18	408.44KB	Share

AVR Capital Raise
27/10/21	PRICE SENSITIVE	173.09KB	Share
AVR Appendix 4D and Half Year Financial Report
26/08/21	PRICE SENSITIVE	956.51KB	Share
AVR Capital Raise
02/08/21	PRICE SENSITIVE	189.44KB	Share
AVR Quarterly Activities/Appendix 4C Cash Flow Report
30/07/21	PRICE SENSITIVE	322.86KB	Share
AVR Trading Halt
29/07/21	PRICE SENSITIVE	631.2KB	Share
AVR AGM Chairman's address and CEO Presentation
15/07/21	PRICE SENSITIVE	7.08MB	Share
AVR ADAPT Conduit Proof of Concept Study finds no Calcification
15/06/21	PRICE SENSITIVE	105.26KB	Share
AVR Capital Raise
24/05/21	PRICE SENSITIVE	164.94KB	Share
AVR Trading Halt
21/05/21	PRICE SENSITIVE	287.87KB	Share
AVR Pause in Trading
21/05/21	PRICE SENSITIVE	116.45KB	Share
AVR ComASUR Key Milestone
27/04/21	PRICE SENSITIVE	191.15KB	Share
AVR Appendix 4C - quarterly
22/04/21	PRICE SENSITIVE	319.41KB	Share
AVR Expanded Funding Package
12/04/21	PRICE SENSITIVE	225.58KB	Share
AVR Anti-Calcification Study
29/03/21	PRICE SENSITIVE	204.67KB	Share
AVR Response to ASX Price and Volume Query
09/03/21	PRICE SENSITIVE	306.69KB	Share
AVR Preliminary Financial Report
18/02/21	PRICE SENSITIVE	228.83KB	Share
AVR Full Year Statutory Accounts
18/02/21	PRICE SENSITIVE	1.73MB	Share
AVR Appendix 4C - quarterly
22/01/21	PRICE SENSITIVE	295.12KB	Share
AVR First Tranche Closing - Mercer
20/01/21	PRICE SENSITIVE	179.92KB	Share
AVR Reinstatement to Official Quotation
06/01/21	PRICE SENSITIVE	86.22KB	Share
AVR Funding Package
06/01/21	PRICE SENSITIVE	294.48KB	Share
AVR Research and Development Advance
04/01/21	PRICE SENSITIVE	158.9KB	Share
AVR Placement
30/12/20	PRICE SENSITIVE	215.3KB	Share
AVR Suspension from Official Quotation
29/12/20	PRICE SENSITIVE	240.75KB	Share
AVR Trading Halt
23/12/20	PRICE SENSITIVE	587.85KB	Share
AVR DurAVR SELECTED AS A BEST INNOVATION - PCR LONDON VALVES
23/11/20	PRICE SENSITIVE	153.04KB	Share
AVR Anti-calcification Comparison Study Interim Results
10/11/20	PRICE SENSITIVE	160.09KB	Share
AVR Appendix 4C - quarterly
16/10/20	PRICE SENSITIVE	272.3KB	Share
AVR Anteris Granted US Patent
08/09/20	PRICE SENSITIVE	177.64KB	Share
AVR Appendix 4D and Half Yearly Financial Report
20/08/20	PRICE SENSITIVE	1.39MB	Share
AVR Unusual Trading Patterns
30/07/20	PRICE SENSITIVE	114.22KB	Share
AVR Response to Market Speculation
24/07/20	PRICE SENSITIVE	595.16KB	Share
AVR Appendix 4C - quarterly
22/07/20	PRICE SENSITIVE	777.31KB	Share
AVR Presentation - Symposium on Next Generation Technologies
21/07/20	PRICE SENSITIVE	2.54MB	Share
AVR Appendix 4C - quarterly
22/04/20	PRICE SENSITIVE	271.76KB	Share
AVR First in human trial commences
27/03/20	PRICE SENSITIVE	100.3KB	Share
AVR Preliminary Financial Report
28/02/20	PRICE SENSITIVE	237.04KB	Share
AVR Appendix 4E and Full Year Accounts
28/02/20	PRICE SENSITIVE	1.42MB	Share
AVR Finalisation of License with 4C Medical
03/02/20	PRICE SENSITIVE	153.58KB	Share
AVR Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	230.25KB	Share
AVR SAVR Clinical Trial
22/01/20	PRICE SENSITIVE	137.57KB	Share
AVR Update to LeMaitre Vascular deal
09/12/19	PRICE SENSITIVE	181.07KB	Share
AVR Response to ASX Price and Volume Query
19/11/19	PRICE SENSITIVE	703.39KB	Share
AVR Appendix 4C - quarterly
31/10/19	PRICE SENSITIVE	282KB	Share
AVR Reinstatement to Official Quotation
14/10/19	PRICE SENSITIVE	71.87KB	Share
AVR CardioCel and VascuCel rights sold to LeMaitre Vascular
14/10/19	PRICE SENSITIVE	111.96KB	Share
AVR Extension for Voluntary Suspension
02/09/19	PRICE SENSITIVE	78.92KB	Share
AVR Appendix 4D and Half Yearly Financial Report
23/08/19	PRICE SENSITIVE	1001.93KB	Share
AVR Suspension from Official Quotation - Annual Listing Fee
22/08/19	PRICE SENSITIVE	440.19KB	Share
AVR Response to ASX Appendix 4C Query
15/08/19	PRICE SENSITIVE	699.37KB	Share
AVR Notice to terminate distribution agreement
08/08/19	PRICE SENSITIVE	75.71KB	Share
AVR Appendix 4C - quarterly
31/07/19	PRICE SENSITIVE	232.24KB	Share
AVR AHZ completes sale of part of Infusion business
31/05/19	PRICE SENSITIVE	93.28KB	Share
AVR 2019 AGM Presentation
14/05/19	PRICE SENSITIVE	2.59MB	Share
AVR Admedus to divest part of Infusion business
13/05/19	PRICE SENSITIVE	121.62KB	Share
AVR Facility Agreement with SIO Partners LP
08/05/19	PRICE SENSITIVE	121.62KB	Share
AVR Appendix 4C - quarterly
26/04/19	PRICE SENSITIVE	267.15KB	Share
AVR Transaction Terminated and Subsidiary Appoints Administrator
23/04/19	PRICE SENSITIVE	94.56KB	Share
AVR Response to ASX Aware Query
23/04/19	PRICE SENSITIVE	270.52KB	Share
AVR Suspension from Official Quotation
17/04/19	PRICE SENSITIVE	290.06KB	Share
AVR Trading Halt
15/04/19	PRICE SENSITIVE	284.95KB	Share
AVR Response to ASX Price and Volume Query
10/04/19	PRICE SENSITIVE	480.15KB	Share
AVR Share Sale Agreement to sell Admedus Vaccines
10/04/19	PRICE SENSITIVE	104.82KB	Share
AVR Trading Halt
10/04/19	PRICE SENSITIVE	150.44KB	Share
AVR Pause In Trading
10/04/19	PRICE SENSITIVE	115.22KB	Share
AVR Preliminary Final Report for period to 31 December 2018
01/03/19	PRICE SENSITIVE	157.47KB	Share
AVR Appendix 4E and Preliminary Final Report
01/03/19	PRICE SENSITIVE	1.69MB	Share
AVR Response to ASX Appendix 4C Query
20/02/19	PRICE SENSITIVE	259.97KB	Share
AVR Promising Interim Results from TAVR Animal Study
19/02/19	PRICE SENSITIVE	100.82KB	Share
AVR Appendix 4C - quarterly
21/01/19	PRICE SENSITIVE	219.42KB	Share
AVR Reinstatement to Official Quotation
28/11/18	PRICE SENSITIVE	68.65KB	Share
AVR Admedus Prospectus - rights issue
28/11/18	PRICE SENSITIVE	655.56KB	Share
AVR Admedus launches rights issue
28/11/18	PRICE SENSITIVE	185.75KB	Share
AVR Appendix 4C - quarterly
01/11/18	PRICE SENSITIVE	365.86KB	Share
AVR Appendix 3B - Star Bright Placement Issue
05/09/18	PRICE SENSITIVE	844.58KB	Share
AVR Appendix 4D and Half Yearly Financial Report
03/09/18	PRICE SENSITIVE	1.02MB	Share
AVR Admedus Secures Strategic Investor
03/09/18	PRICE SENSITIVE	242.06KB	Share
AVR Distribution agreement renewed for infusion supply chain
09/08/18	PRICE SENSITIVE	30.8KB	Share
AVR Voluntary Suspension
06/08/18	PRICE SENSITIVE	276.07KB	Share
AVR Trading Halt Announcement - System Upgrade
06/08/18	PRICE SENSITIVE	220.36KB	Share
AVR Trading Halt
02/08/18	PRICE SENSITIVE	636.94KB	Share
AVR Appendix 4C - quarterly
31/07/18	PRICE SENSITIVE	269.99KB	Share
AVR Major Milestone for TAVR As Trials Commence
11/07/18	PRICE SENSITIVE	615.62KB	Share
AVR New distribution agreement signed for Italy
09/07/18	PRICE SENSITIVE	32.52KB	Share
AVR MOU signed for Admedus Vaccines
27/06/18	PRICE SENSITIVE	633.37KB	Share
AVR Conclusion of relationship with Go Medical Industries
07/06/18	PRICE SENSITIVE	83.13KB	Share
AVR Trading Halt
06/06/18	PRICE SENSITIVE	104.88KB	Share
AVR Appointment of Director
23/05/18	PRICE SENSITIVE	64.89KB	Share
AVR Additional patents filed for TAVR device project
23/05/18	PRICE SENSITIVE	83.52KB	Share
AVR TAVR project progresses to animal trials
22/05/18	PRICE SENSITIVE	100KB	Share
AVR Admedus enters distribution agreement for Spain
17/05/18	PRICE SENSITIVE	74.78KB	Share
AVR Share Purchase Plan
10/05/18	PRICE SENSITIVE	902.27KB	Share
AVR Admedus secures further funding with Placement and SPP
10/05/18	PRICE SENSITIVE	85.36KB	Share
AVR Trading Halt
08/05/18	PRICE SENSITIVE	509.84KB	Share
AVR Appendix 4C - quarterly
30/04/18	PRICE SENSITIVE	139.54KB	Share
AVR Investor signs Letter of Intent to fund Admedus Vaccines
27/04/18	PRICE SENSITIVE	74.84KB	Share
AVR Admedus TAVR gaining momentum with new patent applications
19/04/18	PRICE SENSITIVE	400.23KB	Share
AVR Admedus update on TAVR project
12/03/18	PRICE SENSITIVE	404.36KB	Share
AVR Admedus contracts with US Group Purchasing Organisation
09/03/18	PRICE SENSITIVE	355.81KB	Share
AVR CANADA REGULATORY APPROVAL GRANTED - CARDIOCEL 3D, VASCUCEL
07/03/18	PRICE SENSITIVE	408.44KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $5.60		Change 0.330(6.26%)		Mkt cap ! $86.68M

Open	High	Low	Value	Volume
$5.50	$5.60	$5.30	$89.45K	16.14K

Buyers (Bids)

No.	Vol.	Price($)
1	103	$5.30

Sellers (Offers)

Price($)	Vol.	No.
$5.98	992	1

View Market Depth

No.	Vol.	Price($)
1	103	5.300
1	920	5.270
1	613	5.240
1	576	5.200
1	20000	5.150

Price($)	Vol.	No.
5.980	992	1
5.990	3500	1
6.000	3719	2
6.050	20000	1
6.500	230	2

Last trade - 15.29pm 22/08/2025 (20 minute delay)


Last $5.59		Change 0.330 ( 4.68 %)
Open	High	Low	Volume
$5.59	$5.59	$5.29	3526
Last updated 15.28pm 22/08/2025 ?

AVR (ASX) Chart

ANTERIS TECHNOLOGIES GLOBAL CORP. - Announcements

Corporate Spotlight
Not Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

EV Resources executes strategic MOU with Wogen, XCLR to fund and advance Los Lirios antimony project

Top Stories

ANTERIS TECHNOLOGIES GLOBAL CORP. - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

EV Resources executes strategic MOU with Wogen, XCLR to fund and advance Los Lirios antimony project

Top Stories

Corporate Spotlight
Not Yet Available